Passage Bio Stock Analysis

PASG Stock  USD 0.48  0.01  1.28%   
Passage Bio is undervalued with Real Value of 2.35 and Target Price of 8.0. The main objective of Passage Bio stock analysis is to determine its intrinsic value, which is an estimate of what Passage Bio is worth, separate from its market price. There are two main types of Passage Bio's stock analysis: fundamental analysis and technical analysis.
The Passage Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Passage Bio's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

Passage Stock Analysis Notes

About 61.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Passage Bio recorded a loss per share of 1.07. The entity had not issued any dividends in recent years. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To find out more about Passage Bio contact William MD at 267 866 0311 or learn more at https://www.passagebio.com.

Passage Bio Investment Alerts

Passage Bio generated a negative expected return over the last 90 days
Passage Bio has high historical volatility and very poor performance
Passage Bio has some characteristics of a very speculative penny stock
Passage Bio has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0.
Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Passage Bio has a frail financial position based on the latest SEC disclosures
Roughly 61.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 75007 shares by Orbimed Advisors Llc of Passage Bio at 0.68 subject to Rule 16b-3

Passage Bio Upcoming and Recent Events

4th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Passage Largest EPS Surprises

Earnings surprises can significantly impact Passage Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-08
2024-06-30-0.31-0.260.0516 
2024-05-14
2024-03-31-0.36-0.30.0616 
2024-03-04
2023-12-31-0.4-0.30.125 
View All Earnings Estimates

Passage Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Shay Capital Llc2024-12-31
225.3 K
Fiduciary Trust Co2024-12-31
215 K
State Street Corp2024-12-31
156.8 K
Millennium Management Llc2024-12-31
148.6 K
Rbf Llc2024-12-31
142.8 K
Jane Street Group Llc2024-12-31
78.2 K
Squarepoint Ops Llc2024-12-31
64.1 K
Northern Trust Corp2024-12-31
62.5 K
Tower Research Capital Llc2024-12-31
54.5 K
Orbimed Advisors, Llc2024-12-31
7.4 M
Vestal Point Capital Lp2024-12-31
6.1 M
Note, although Passage Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Passage Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.9 M.

Passage Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.63)(0.66)
Return On Capital Employed(0.85)(0.89)
Return On Assets(0.63)(0.66)
Return On Equity(1.06)(1.00)

Management Efficiency

Passage Bio has return on total asset (ROA) of (0.322) % which means that it has lost $0.322 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7507) %, meaning that it created substantial loss on money invested by shareholders. Passage Bio's management efficiency ratios could be used to measure how well Passage Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.66. The current Return On Capital Employed is estimated to decrease to -0.89. At this time, Passage Bio's Non Current Assets Total are most likely to increase significantly in the upcoming years. The Passage Bio's current Total Current Assets is estimated to increase to about 141.2 M, while Total Assets are projected to decrease to roughly 97.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 1.01  0.96 
Tangible Book Value Per Share 1.01  0.96 
Enterprise Value Over EBITDA(0.31)(0.33)
Price Book Value Ratio 0.56  0.59 
Enterprise Value Multiple(0.31)(0.33)
Price Fair Value 0.56  0.59 
Enterprise Value22.2 M21.1 M
Leadership at Passage Bio emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta
1.547
Return On Assets
(0.32)
Return On Equity
(0.75)

Technical Drivers

As of the 21st of March, Passage Bio holds the Risk Adjusted Performance of (0.05), coefficient of variation of (1,573), and Variance of 56.96. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Passage Bio, as well as the relationship between them. Please check Passage Bio standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if Passage Bio is priced some-what accurately, providing market reflects its current price of 0.47600001 per share. As Passage Bio is a penny stock we also suggest to check out its jensen alpha numbers.

Passage Bio Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Passage Bio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Passage Bio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Passage Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Passage Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Passage Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Passage Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Orbimed Advisors Llc 2 days ago
Disposition of 75007 shares by Orbimed Advisors Llc of Passage Bio at 0.68 subject to Rule 16b-3
 
Cale Edgar B. few days ago
Acquisition by Cale Edgar B. of 278386 shares of Passage Bio at 0.387 subject to Rule 16b-3
 
Cale Edgar B. over a week ago
Acquisition by Cale Edgar B. of 50000 shares of Passage Bio subject to Rule 16b-3
 
Kathleen Borthwick over a month ago
Disposition of 3183 shares by Kathleen Borthwick of Passage Bio at 0.5296 subject to Rule 16b-3
 
Kathleen Borthwick over a month ago
Disposition of 8000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3
 
Fotopoulos Alexandros over a month ago
Disposition of 12500 shares by Fotopoulos Alexandros of Passage Bio subject to Rule 16b-3
 
Chou William over a month ago
Acquisition by Chou William of 575000 shares of Passage Bio at 1.5 subject to Rule 16b-3
 
Sondhi Dolan over a month ago
Acquisition by Sondhi Dolan of 092 shares of Passage Bio at 1.28 subject to Rule 16b-3
 
Sondhi Dolan over a month ago
Acquisition by Sondhi Dolan of 48000 shares of Passage Bio at 0.848 subject to Rule 16b-3
 
Orbimed Advisors Llc over two months ago
Disposition of 79024 shares by Orbimed Advisors Llc of Passage Bio at 0.6 subject to Rule 16b-3
 
Orbimed Advisors Llc over two months ago
Disposition of 17986 shares by Orbimed Advisors Llc of Passage Bio at 0.64 subject to Rule 16b-3
 
Orbimed Advisors Llc over two months ago
Disposition of 75007 shares by Orbimed Advisors Llc of Passage Bio at 0.68 subject to Rule 16b-3

Passage Bio Outstanding Bonds

Passage Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Passage Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Passage bonds can be classified according to their maturity, which is the date when Passage Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Passage Bio Predictive Daily Indicators

Passage Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Passage Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Passage Bio Forecast Models

Passage Bio's time-series forecasting models are one of many Passage Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Passage Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Passage Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Passage Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Passage shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Passage Bio. By using and applying Passage Stock analysis, traders can create a robust methodology for identifying Passage entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Passage Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Passage analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Passage analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
8.0Strong Buy4Odds
Passage Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Passage analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Passage stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Passage Bio, talking to its executives and customers, or listening to Passage conference calls.
Passage Analyst Advice Details

Passage Stock Analysis Indicators

Passage Bio stock analysis indicators help investors evaluate how Passage Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Passage Bio shares will generate the highest return on investment. By understating and applying Passage Bio stock analysis, traders can identify Passage Bio position entry and exit signals to maximize returns.
Begin Period Cash Flow21.7 M
Common Stock Shares Outstanding60.4 M
Total Stockholder Equity61.3 M
Property Plant And Equipment Net23.1 M
Cash And Short Term Investments76.8 M
Cash37.6 M
Accounts Payable742 K
Net Debt-12.1 M
50 Day M A0.5439
Total Current Liabilities19.4 M
Non Current Assets Total23.6 M
Non Currrent Assets Other463 K
Stock Based Compensation5.8 M

Complementary Tools for Passage Stock analysis

When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Stocks Directory
Find actively traded stocks across global markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios